Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

PARP inhibitors are approved for treating advanced prostate cancers (APC) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B phase II clinical trial samples, evaluating whole-exome and low-pass whol...

Descripción completa

Detalles Bibliográficos
Autores principales: Carreira, Suzanne, Porta, Nuria, Arce-Gallego, Sara, Seed, George, Llop-Guevara, Alba, Bianchini, Diletta, Rescigno, Pasquale, Paschalis, Alec, Bertan, Claudia, Baker, Chloe, Goodall, Jane, Miranda, Susana, Riisnaes, Ruth, Figueiredo, Ines, Ferreira, Ana, Pereira, Rita, Crespo, Mateus, Gurel, Bora, Nava Rodrigues, Daniel, Pettitt, Stephen J., Yuan, Wei, Serra, Violeta, Rekowski, Jan, Lord, Christopher J., Hall, Emma, Mateo, Joaquin, de Bono, Johann S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414325/
https://www.ncbi.nlm.nih.gov/pubmed/34045297
http://dx.doi.org/10.1158/2159-8290.CD-21-0007